UCB Japan, a leading global biopharmaceutical company has obtained the approval of Keppra - generic name levetiracetam - 500mg/5mL (100mg/mL) from the U.S. Food and Drug Administration (FDA) for use as an adjunctive therapy for treatment of partial-onset seizures in adults with epilepsy.
